Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of “Hold” by Analysts

Shares of Novavax, Inc. (NASDAQ:NVAX) have received a consensus recommendation of “Hold” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $17.83.

Several research analysts have recently commented on the company. Jefferies Financial Group decreased their price objective on shares of Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, October 16th. B. Riley reissued a “buy” rating and issued a $26.00 price target (up previously from $23.00) on shares of Novavax in a research note on Thursday, October 10th. Finally, HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of Novavax in a research report on Tuesday, December 10th.

Institutional Trading of Novavax

A number of large investors have recently made changes to their positions in NVAX. Banque Cantonale Vaudoise boosted its holdings in shares of Novavax by 500.0% in the second quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 2,500 shares during the last quarter. Amalgamated Bank raised its position in Novavax by 26.9% in the second quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 1,036 shares during the period. Signaturefd LLC boosted its stake in shares of Novavax by 214.5% during the 2nd quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company’s stock worth $72,000 after acquiring an additional 3,874 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Novavax by 38.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 1,598 shares during the period. Finally, Midland Wealth Advisors LLC purchased a new stake in shares of Novavax in the 2nd quarter worth $152,000. 53.04% of the stock is currently owned by institutional investors.

Novavax Price Performance

NASDAQ NVAX opened at $8.64 on Tuesday. The company’s 50 day simple moving average is $9.05 and its two-hundred day simple moving average is $11.75. Novavax has a 1 year low of $3.53 and a 1 year high of $23.86. The stock has a market capitalization of $1.38 billion, a PE ratio of -3.82 and a beta of 2.02.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.07. The business had revenue of $84.51 million during the quarter, compared to analysts’ expectations of $65.80 million. During the same quarter last year, the business posted ($1.26) EPS. The company’s quarterly revenue was down 54.8% on a year-over-year basis. On average, research analysts anticipate that Novavax will post -1.44 EPS for the current year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.